BioSpace News Archive

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders

Combined Therapeutics Inc. announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the World Vaccine Congress Europe 2023, taking place from October 17 to 19 in Barcelona, Spain.

Codagenix Inc. announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.

AtriCure, Inc. today announced that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

Ichnos Sciences today announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases.

Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.

Scholar Rock Holding Corporation, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share.

Faron Pharmaceuticals Ltd. announces updated data from the Phase 1/2 BEXMAB study investigating bexmarilimab in combination with standard of care in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes patients having failed hypomethylating agents.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that Susan Mahony, PhD, has been appointed to Axsome’s board of directors, effective immediately.